bifidobacterium tetrad live bacteria tablet placebo + helicobacter pylori quadruple eradication therapy

This term refers to the control arm in clinical trials evaluating the efficacy of Bifidobacterium tetrad live bacteria tablets (brand name: Si Lian Kang) as an adjunct to standard Helicobacter pylori eradication therapy. The regimen consists of a standard bismuth-containing quadruple therapy—typically a combination of a proton pump inhibitor (PPI), bismuth, and two antibiotics—administered alongside an inactive placebo tablet instead of the live probiotic. Developed by Hangzhou Grand Biologic Pharmaceutical, this combination is used to establish a baseline for H. pylori eradication rates and the incidence of antibiotic-associated gastrointestinal side effects, such as diarrhea and abdominal pain, in patients with peptic ulcers or gastritis.

Brand names

Si Lian Kang

Other names

placebo + H. pylori quadruple therapyquadruple eradication therapy plus placebo